Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Sales (2016 - 2025)

Protalix BioTherapeutics has reported Return on Sales over the past 16 years, most recently at 0.12% for Q4 2025.

  • Quarterly results put Return on Sales at 0.12% for Q4 2025, down 74.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (down 19.0% YoY), and the annual figure for FY2025 was 0.04%, down 18.0%.
  • Return on Sales for Q4 2025 was 0.12% at Protalix BioTherapeutics, down from 0.14% in the prior quarter.
  • Over the last five years, Return on Sales for PLX hit a ceiling of 0.62% in Q4 2024 and a floor of 1.77% in Q4 2023.
  • Median Return on Sales over the past 5 years was 0.29% (2022), compared with a mean of 0.37%.
  • Biggest five-year swings in Return on Sales: crashed -140bps in 2023 and later soared 239bps in 2024.
  • Protalix BioTherapeutics' Return on Sales stood at 0.77% in 2021, then soared by 52bps to 0.37% in 2022, then crashed by -376bps to 1.77% in 2023, then surged by 135bps to 0.62% in 2024, then plummeted by -120bps to 0.12% in 2025.
  • The last three reported values for Return on Sales were 0.12% (Q4 2025), 0.14% (Q3 2025), and 0.01% (Q2 2025) per Business Quant data.